Literature DB >> 22008816

Active immunization against IL-23p19 improves experimental arthritis.

Rojo Anthony Ratsimandresy1, Emilie Duvallet, Eric Assier, Luca Semerano, Laure Delavallée, Natacha Bessis, Jean-François Zagury, Marie-Christophe Boissier.   

Abstract

INTRODUCTION: IL-23 is a pro-inflammatory cytokine essential for the differentiation of Th17 lymphocytes, a subtype of T lymphocyte implied in auto-immunity. IL-23 shares a subunit with IL-12, IL-12/23p40, and comprises a specific subunit, IL-23p19. We previously demonstrated that active immunization against entire TNF-α and against peptides of IL-1β was protective in animal models of rheumatoid arthritis. The aim of this study was to evaluate the effect of peptide-based vaccines targeting the IL-23p19 subunit in collagen-induced arthritis (CIA).
METHODS: Using bioinformatics, the murine IL-23p19 subunit was modeled and two peptides were defined in the receptor interacting domain. Each peptide was coupled to keyhole limpet hemocyanin (KLH) to obtain two vaccines IL23-K1 and IL23-K2. Both vaccines were used for immunizations in incomplete Freund adjuvant (IFA) in groups of DBA/1 mice. Control groups received KLH or PBS at the same dates. CIA was induced by two subcutaneous injections of bovine type II collagen (CIIb), and the development of disease assessed during the next two months. Anti-CIIb and anti-IL-23 antibody levels were assessed by ELISA. Pro- and anti-inflammatory cytokines mRNA were quantified by qRT-PCR in the spleen and the synovium. T-cell populations in the spleen were evaluated by FACS analysis.
RESULTS: The clinical scores showed that mice treated with IL23-K1 developed less arthritis than negative controls (p<0.05). Mice immunized with IL23-K1 produced more anti-IL-23 antibodies than those immunized with IL23-K2 (p<0.001). mRNA quantification showed that the IL23-K1 immunization led to an increase of IL-10 in the spleen (p<0.05 vs. KLH), without any effect on IL-17 level. Histological examination showed that IL23-K1 strongly protected against joint destruction and inflammation (p<0.01 vs. KLH and p<0.001 vs. PBS). T-cell populations in the spleen were not modified by IL-23 modulation.
CONCLUSION: These data show that targeting IL-23p19 through a vaccination strategy is protective in CIA. This specific targeting of IL-23 might constitute a promising therapeutic approach to explore in rheumatoid arthritis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008816     DOI: 10.1016/j.vaccine.2011.09.134

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

Review 1.  Arthritis models: usefulness and interpretation.

Authors:  Natacha Bessis; Patrice Decker; Eric Assier; Luca Semerano; Marie-Christophe Boissier
Journal:  Semin Immunopathol       Date:  2017-03-27       Impact factor: 9.623

Review 2.  Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis.

Authors:  Zheni Stavre; Katherine Upchurch; Jonathan Kay; Ellen M Gravallese
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

3.  Effect of the blockade of the IL-23-Th17-IL-17A pathway on streptozotocin-induced diabetic retinopathy in rats.

Authors:  Haiyan Xu; Min Cai; Xuedong Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-05       Impact factor: 3.117

Review 4.  Possible roles of IL-12-family cytokines in rheumatoid arthritis.

Authors:  Richard M Pope; Shiva Shahrara
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

Review 5.  Cytokine-modulating strategies and newer cytokine targets for arthritis therapy.

Authors:  Shivaprasad H Venkatesha; Steven Dudics; Bodhraj Acharya; Kamal D Moudgil
Journal:  Int J Mol Sci       Date:  2014-12-31       Impact factor: 5.923

Review 6.  Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis.

Authors:  Reka Kugyelka; Zoltan Kohl; Katalin Olasz; Katalin Mikecz; Tibor A Rauch; Tibor T Glant; Ferenc Boldizsar
Journal:  Mediators Inflamm       Date:  2016-01-20       Impact factor: 4.711

7.  Immunization against an IL-6 peptide induces anti-IL-6 antibodies and modulates the Delayed-Type Hypersensitivity reaction in cynomolgus monkeys.

Authors:  Lucille Desallais; Caroline Bouchez; Hadley Mouhsine; Gabriel Moreau; Rojo Ratsimandresy; Matthieu Montes; Hervé Do; Françoise Quintin-Colonna; Jean-François Zagury
Journal:  Sci Rep       Date:  2016-01-19       Impact factor: 4.379

8.  IL-1 Vaccination Is Suitable for Treating Inflammatory Diseases.

Authors:  Eric Assier; Natacha Bessis; Jean-François Zagury; Marie-Christophe Boissier
Journal:  Front Pharmacol       Date:  2017-01-31       Impact factor: 5.810

9.  Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.

Authors:  Lucille Desallais; Jérôme Avouac; Maxime Fréchet; Muriel Elhai; Rojo Ratsimandresy; Matthieu Montes; Hadley Mouhsine; Hervé Do; Jean-François Zagury; Yannick Allanore
Journal:  Arthritis Res Ther       Date:  2014-07-24       Impact factor: 5.156

10.  Interleukin-23 may contribute to the pathogenesis of lumbar disc herniation through the IL-23/IL-17 pathway.

Authors:  Hongqiang Jiang; Yao Deng; Tao Wang; Jianxiong Ma; Pengfei Li; Peng Tian; Chao Han; Xinlong Ma
Journal:  J Orthop Surg Res       Date:  2016-01-16       Impact factor: 2.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.